Real-world treatment patterns and outcomes in patients with HR+/HER2- metastatic breast cancer treated with chemotherapy in the United States.
S M TolaneyK PunieL A CareyA W KurianI NtallaN SjeklocaA ShahM K RehnquistM StokesK FraemanW VerretK Jhaveri
Published in: ESMO open (2024)
This real-world study demonstrates that for patients with HR+/HER2- mBC, chemotherapy provides relatively limited survival benefit which decreases with each additional chemotherapy line, and highlights the need for improved treatment options.